Therapeutic vaccines designed to treat cancer and other disorders by triggering the immune system to attack certain proteins may become one of GlaxoSmithKline's important product lines, CEO Andrew Witty said. The drugmaker is conducting late-stage studies of MAGE-A3, a vaccine against lung cancer and melanoma that targets MAGE-3 -- a protein common in some cancers but not in healthy cells.

Full Story:

Related Summaries